Aldeyra The
NASDAQ: ALDX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Todd C. Brady
- Employees
- 8
- Headquarters
- Lexington, United States
- IPO year
- 2014
- Market cap
- $114.6M
- Website
- https://www.aldeyra.com
Loading ALDX…
Loading profile data…Frequently asked questions about ALDX
What does Aldeyra The (ALDX) do?
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofol...
Where does ALDX trade?
Aldeyra The (ALDX) trades on the NASDAQ.
What sector is ALDX in?
Aldeyra The (ALDX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Aldeyra The?
Todd C. Brady is the chief executive officer of Aldeyra The (ALDX).
Where is Aldeyra The headquartered?
Aldeyra The is headquartered in United States.
Does ALDX pay a dividend?
Aldeyra The (ALDX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALDX go public?
Aldeyra The (ALDX) completed its initial public offering in 2014.